Alnylam Pharmaceuticals | ALNY - Current Assets



Alnylam Pharmaceuticals reported $3.64B in Current Assets for its fiscal quarter ending in June of 2025.


Current Assets Change Date
Acadia Pharmaceuticals USD 960.55M 89.61M Jun/2025
Agios Pharmaceuticals USD 1.02B 50.85M Jun/2025
Alnylam Pharmaceuticals USD 3.64B 375.44M Jun/2025
Amgen USD 26.73B 195M Jun/2025
Arrowhead Research USD 946.92M 188.3M Jun/2025
BioMarin Pharmaceutical USD 3.81B 337.43M Jun/2025
Incyte USD 3.64B 411.91M Jun/2025
Ionis Pharmaceuticals USD 2.58B 158.22M Jun/2025
Moderna USD 6.17B 595M Jun/2025
Neurocrine Biosciences USD 1.75B 111M Jun/2025
Novartis USD 25.94B 3.76B Jun/2025
PTC Therapeutics USD 2.27B 43.53M Jun/2025
Regeneron Pharmaceuticals USD 16.86B 712.2M Jun/2025
Sanofi 37.02B 5.57B Jun/2025
Sarepta Therapeutics USD 2.66B 224.45M Jun/2025
Takeda JPY 2.51T 8.07B Jun/2025
Tectonic Therapeutic USD 290.85M 143.99M Jun/2025
Ultragenyx Pharmaceutical USD 719.79M 20.63M Jun/2025
Vertex Pharmaceuticals USD 10.43B 419.1M Jun/2025
Xencor USD 513.15M 8.12M Jun/2025